What is Keros Therapeutics's market cap?

Keros Therapeutics (KROS) has a market capitalization of $202.1M and trades on NASDAQ.

Who are Keros Therapeutics's competitors?

Keros Therapeutics's key competitors include Scholar Rock Holding Corporation, Geron Corporation, Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does Keros Therapeutics partner with?

Keros Therapeutics's notable partners include Takeda Pharmaceuticals U.S.A., Inc., Hansoh (Shanghai) Healthtech Co., Ltd., The General Hospital Corporation.

Where is Keros Therapeutics headquartered?

Keros Therapeutics is headquartered in United States of America and employs approximately 141 people. It has been publicly traded since 2020.

Keros Therapeutics

KROS

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel protein therapeutics for disorders linked to dysfunctional TGF-beta signaling.

Market cap

$202.07M-65.6%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$367.0KMiss by $1.6M EPS-$1.21Miss by $0.19

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$807.1K

EPS estimate-$1.25

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Bristol-Myers Squibb$127.75B+32.1%

Scholar Rock$5.9B+66.5%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Geron$949.5M+29.6%

Keros Therapeutics$202.1M-65.7%

Atrium Therapeutics $197.9M-95.2%

KYN

Kyntra Bio, Inc.$28.5M—

By revenue growth

Geron+537%

Scholar Rock+76.4%

Sarepta Therapeutics, Inc.+9.9%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

By net margin

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

Sarepta Therapeutics, Inc.4.64%-38.4pp

Scholar Rock-236.95%+173pp

Geron-682.47%+436pp

Profile

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel protein therapeutics for disorders linked to dysfunctional TGF-beta signaling. By targeting master regulators of tissue growth and repair, the company aims to provide disease-modifying treatments for neuromuscular and hematological diseases, including Duchenne muscular dystrophy and myelodysplastic syndromes.

Competitive position

A clinical-stage leader in TGF-beta signaling pathways with a proprietary library of ActRII ligand traps and strategic global partnerships.

GeographiesUnited States, Global

Customer segmentsRare disease patients, Pharmaceutical companies

Business modelR&D intensive, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Academic research institutions, Clinical trial sites

CustomersStrategic licensing partners, Specialty pharmacies, Hospitals and clinics

CountryUnited States of America

Listed2020

Employees141.0

CEOJasbir S. Seehra

SectorHealthcare

IndustryBiotechnology

Websitekerostx.com

FilingsSEC EDGAR

Questions, answered.

What is Keros Therapeutics's market cap?: Keros Therapeutics (KROS) has a market capitalization of $202.1M and trades on NASDAQ.
Who are Keros Therapeutics's competitors?: Keros Therapeutics's key competitors include Scholar Rock Holding Corporation, Geron Corporation, Sarepta Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does Keros Therapeutics partner with?: Keros Therapeutics's notable partners include Takeda Pharmaceuticals U.S.A., Inc., Hansoh (Shanghai) Healthtech Co., Ltd., The General Hospital Corporation.
Where is Keros Therapeutics headquartered?: Keros Therapeutics is headquartered in United States of America and employs approximately 141 people. It has been publicly traded since 2020.